Cover Image
市場調查報告書

經導管心臟瓣膜:醫療設備的開發平台評估

Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 408772
出版日期 內容資訊 英文 284 Pages
訂單完成後即時交付
價格
Back to Top
經導管心臟瓣膜:醫療設備的開發平台評估 Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年10月11日 內容資訊: 英文 284 Pages
簡介

本報告提供全球經導管心臟瓣膜市場上主要的開發中產品 (醫療設備) 及其臨床實驗的進展調查,再彙整產品特性比較分析 (臨床實驗的各進展階段) ,主要企業簡介及代表性產品,近來的市場動靜 (資本交易·產業聯盟等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 經導管心臟瓣膜概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各市場區隔
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 經導管心臟瓣膜:各企業現在臨床實驗中的開發中產品

  • 經導管心臟瓣膜的企業:各臨床實驗階段的開發中產品
  • 經導管心臟瓣膜:各臨床實驗階段的開發中產品

第5章 經導管心臟瓣膜的企業·產品概要

  • Abbott Vascular Inc.
    • 開發中產品及進行中的臨床實驗概要
  • Admedus Ltd
  • Advanced Bio Prosthetic Surfaces Ltd.
  • Aegis Surgical Limited
  • Annulon
  • AorTech International Plc
  • Arbor Surgical Technologies, Inc.
  • Boston Scientific Corp
  • Celyad SA
  • Cephea Valve Technologies, Inc.
  • Children's Hospital Boston
  • Clemson University
  • Colibri Heart Valve, LLC
  • Direct Flow Medical Inc
  • Dura LLC
  • Edwards Lifesciences Corp
  • Emory University
  • Endoluminal Technology Research, LLC
  • Hansen Medical Inc
  • HighLife SAS
  • HLT, Inc.
  • InterVene Inc.
  • JC Medical, Inc.
  • JenaValve Technology GmbH
  • Mayo Clinic US
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • Micro Interventional Devices, Inc.
  • MicroPort Scientific Corp
  • Mitralix Ltd.
  • MitrAssist Ltd.
  • MValve Technologies Ltd.
  • NaviGate Cardiac Structures, Inc.
  • Neovasc Inc
  • PolyNova Cardiovascular LLC
  • RegenaGraft
  • SAS Cormove
  • Sino Medical Sciences Technology Inc.
  • St. Jude Medical Inc
  • Symetis AG
  • Thubrikar Aortic Valve, Inc.
  • Universiteit Utrecht
  • University College London
  • University of California San Francisco
  • University of Cambridge
  • University of Iowa
  • Valtech Cardio Ltd
  • Venus MedTech
  • Xeltis AG

第6章 經導管心臟瓣膜市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0481EPD

GlobalData's Medical Devices sector report, "Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2017" provides an overview of Transcatheter Heart Valves currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Heart Valves pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Transcatheter Heart Valves under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transcatheter Heart Valves and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transcatheter Heart Valves under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 16

2 Introduction 17

  • 2.1 Transcatheter Heart Valves Overview 17

3 Products under Development 18

  • 3.1 Transcatheter Heart Valves - Pipeline Products by Stage of Development 18
  • 3.2 Transcatheter Heart Valves - Pipeline Products by Segment 19
  • 3.3 Transcatheter Heart Valves - Pipeline Products by Territory 20
  • 3.4 Transcatheter Heart Valves - Pipeline Products by Regulatory Path 21
  • 3.5 Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date 22
  • 3.6 Transcatheter Heart Valves - Ongoing Clinical Trials 23

4 Transcatheter Heart Valves - Pipeline Products under Development by Companies 24

  • 4.1 Transcatheter Heart Valves Companies - Pipeline Products by Stage of Development 24
  • 4.2 Transcatheter Heart Valves - Pipeline Products by Stage of Development 26

5 Transcatheter Heart Valves Companies and Product Overview 29

  • 5.1 4C Medical Technologies Inc Company Overview 29
    • 5.1.1 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.2 Admedus Ltd Company Overview 30
    • 5.2.1 Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.3 Aegis Surgical Limited Company Overview 31
    • 5.3.1 Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.4 Annulon Company Overview 32
    • 5.4.1 Annulon Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.5 AorTech International Plc Company Overview 33
    • 5.5.1 AorTech International Plc Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.6 Arbor Surgical Technologies, Inc. Company Overview 34
    • 5.6.1 Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.7 Boston Scientific Corp Company Overview 35
    • 5.7.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.8 Celyad SA Company Overview 65
    • 5.8.1 Celyad SA Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.9 Cephea Valve Technologies, Inc. Company Overview 66
    • 5.9.1 Cephea Valve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.10 Children's Hospital Boston Company Overview 67
    • 5.10.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.11 Clemson University Company Overview 68
    • 5.11.1 Clemson University Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.12 Colibri Heart Valve, LLC Company Overview 69
    • 5.12.1 Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.13 Daidalos Solutions BV Company Overview 74
    • 5.13.1 Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 74
  • 5.14 Direct Flow Medical Inc Company Overview 76
    • 5.14.1 Direct Flow Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 76
  • 5.15 DSM Dyneema B.V. Company Overview 81
    • 5.15.1 DSM Dyneema B.V. Pipeline Products & Ongoing Clinical Trials Overview 81
  • 5.16 Dura LLC Company Overview 82
    • 5.16.1 Dura LLC Pipeline Products & Ongoing Clinical Trials Overview 82
  • 5.17 Edwards Lifesciences Corp Company Overview 85
    • 5.17.1 Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 85
  • 5.18 Emory University Company Overview 103
    • 5.18.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 103
  • 5.19 Endoluminal Technology Research, LLC Company Overview 104
    • 5.19.1 Endoluminal Technology Research, LLC Pipeline Products & Ongoing Clinical Trials Overview 104
  • 5.20 Florida International University Company Overview 106
    • 5.20.1 Florida International University Pipeline Products & Ongoing Clinical Trials Overview 106
  • 5.21 Hansen Medical Inc Company Overview 107
    • 5.21.1 Hansen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 107
  • 5.22 HighLife SAS Company Overview 108
    • 5.22.1 HighLife SAS Pipeline Products & Ongoing Clinical Trials Overview 108
  • 5.23 HLT, Inc. Company Overview 111
    • 5.23.1 HLT, Inc. Pipeline Products & Ongoing Clinical Trials Overview 111
  • 5.24 InterVene Inc. Company Overview 114
    • 5.24.1 InterVene Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
  • 5.25 JC Medical, Inc. Company Overview 117
    • 5.25.1 JC Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 117
  • 5.26 JenaValve Technology GmbH Company Overview 120
    • 5.26.1 JenaValve Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 120
  • 5.27 LivaNova PLC Company Overview 123
    • 5.27.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 123
  • 5.28 Mayo Clinic US Company Overview 126
    • 5.28.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 126
  • 5.29 Medtronic plc Company Overview 127
    • 5.29.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 127
  • 5.30 Meril Life Sciences Pvt Ltd Company Overview 137
    • 5.30.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 137
  • 5.31 Micro Interventional Devices, Inc. Company Overview 138
    • 5.31.1 Micro Interventional Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 138
  • 5.32 MicroPort Scientific Corp Company Overview 139
    • 5.32.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 139
  • 5.33 Mitralix Ltd. Company Overview 142
    • 5.33.1 Mitralix Ltd. Pipeline Products & Ongoing Clinical Trials Overview 142
  • 5.34 MitrAssist Ltd. Company Overview 143
    • 5.34.1 MitrAssist Ltd. Pipeline Products & Ongoing Clinical Trials Overview 143
  • 5.35 MValve Technologies Ltd. Company Overview 144
    • 5.35.1 MValve Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 144
  • 5.36 NaviGate Cardiac Structures, Inc. Company Overview 147
    • 5.36.1 NaviGate Cardiac Structures, Inc. Pipeline Products & Ongoing Clinical Trials Overview 147
  • 5.37 Neovasc Inc Company Overview 151
    • 5.37.1 Neovasc Inc Pipeline Products & Ongoing Clinical Trials Overview 151
  • 5.38 PolyNova Cardiovascular LLC Company Overview 154
    • 5.38.1 PolyNova Cardiovascular LLC Pipeline Products & Ongoing Clinical Trials Overview 154
  • 5.39 RegenaGraft Company Overview 155
    • 5.39.1 RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview 155
  • 5.40 SAS Cormove Company Overview 156
    • 5.40.1 SAS Cormove Pipeline Products & Ongoing Clinical Trials Overview 156
  • 5.41 Sino Medical Sciences Technology Inc Company Overview 157
    • 5.41.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 157
  • 5.42 St. Jude Medical LLC Company Overview 158
    • 5.42.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 158
  • 5.43 Symetis AG Company Overview 162
    • 5.43.1 Symetis AG Pipeline Products & Ongoing Clinical Trials Overview 162
  • 5.44 Thubrikar Aortic Valve, Inc. Company Overview 173
    • 5.44.1 Thubrikar Aortic Valve, Inc. Pipeline Products & Ongoing Clinical Trials Overview 173
  • 5.45 Trinity College Dublin Company Overview 174
    • 5.45.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 174
  • 5.46 University College London Company Overview 175
    • 5.46.1 University College London Pipeline Products & Ongoing Clinical Trials Overview 175
  • 5.47 University of California San Francisco Company Overview 177
    • 5.47.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 177
  • 5.48 University of Cambridge Company Overview 178
    • 5.48.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 178
  • 5.49 University of Iowa Company Overview 179
    • 5.49.1 University of Iowa Pipeline Products & Ongoing Clinical Trials Overview 179
  • 5.50 Valtech Cardio Ltd Company Overview 181
    • 5.50.1 Valtech Cardio Ltd Pipeline Products & Ongoing Clinical Trials Overview 181
  • 5.51 Vascular Concepts Ltd Company Overview 182
    • 5.51.1 Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview 182
  • 5.52 Venus MedTech Company Overview 183
    • 5.52.1 Venus MedTech Pipeline Products & Ongoing Clinical Trials Overview 183
  • 5.53 Xeltis AG Company Overview 190
    • 5.53.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 190

6 Transcatheter Heart Valves- Recent Developments 191

  • 6.1 Sep 21, 2017: Medtronic Announces Clinical Study to Evaluate the CoreValve Evolut PRO System in 'Everyday' Clinical Practice 191
  • 6.2 Sep 12, 2017: Neovasc Provides Tiara Clinical Update 191
  • 6.3 Sep 11, 2017: MPSC Achieves Substantial Growth in 1H 2017 Net Profit Increases 272.4% YOY 192
  • 6.4 Sep 01, 2017: Decision from Appeals Court upholds lower court decisions but denies injunction 194
  • 6.5 Aug 30, 2017: NaviGate Cardiac Structures reports world's first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient 194
  • 6.6 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 196
  • 6.7 Aug 16, 2017: AorTech International: Audited results for the year ended 31 March 2017 198
  • 6.8 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 200
  • 6.9 Aug 10, 2017: Neovasc Announces Results for the Second Quarter of 2017 200
  • 6.10 Aug 03, 2017: 4C Medical's Novel Mitral Regurgitation Therapy Highlighted at CVI 2017 Innovation Summit 203
  • 6.11 Jul 31, 2017: Medtronic Announces CE Mark and European Launch of CoreValve Evolut PRO Transcatheter Valve with Advanced Sealing 204
  • 6.12 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 205
  • 6.13 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 206
  • 6.14 Jul 10, 2017: Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval 207
  • 6.15 Jul 07, 2017: MPSC New COO Glendy Wang on Board 208
  • 6.16 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 208
  • 6.17 Jun 16, 2017: Neovasc Announces German Court Ruling 210
  • 6.18 Jun 15, 2017: Neovasc Tiara Featured in TVT 2017 Presentation 210
  • 6.19 Jun 15, 2017: 4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum 211
  • 6.20 Jun 06, 2017: First U.S. Patients Enrolled in an Early Feasibility Study of HLT's New Transcatheter Aortic Valve Replacement System 212
  • 6.21 Jun 05, 2017: FDA expands use of Sapien 3 artificial heart valve for high-risk patients 212
  • 6.22 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 213
  • 6.23 May 19, 2017: Celyad Announces First Quarter 2017 Business Update 216
  • 6.24 May 17, 2017: Edwards' Novel Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes 217
  • 6.25 May 16, 2017: Real-World Evidence With Edwards SAPIEN 3 Transcatheter Valve Confirms Beneficial Patient Outcomes From Clinical Trials 218
  • 6.26 May 16, 2017: The Boston Scientific LOTUS Valve System Demonstrated Superior Efficacy to CoreValve in Global REPRISE III Trial at One Year 219
  • 6.27 May 16, 2017: New Data on CoreValve and Evolut R Self-Expanding TAVI Systems Show Excellent Clinical Outcomes in Routine Clinical Practice 219
  • 6.28 May 11, 2017: Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR 220
  • 6.29 May 10, 2017: Boston Scientific to Present The LOTUS Valve System at EuroPCR 2017 221
  • 6.30 May 10, 2017: Neovasc Announces Results for the First Quarter of 2017 222
  • 6.31 Apr 28, 2017: Venus Medtech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China English 224
  • 6.32 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 225
  • 6.33 Apr 26, 2017: NaviGate Cardiac Structures Reports First Heterotopic Transcatheter GATE Tricuspid Valved Stent Successful Implantation 226
  • 6.34 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results 227
  • 6.35 Apr 05, 2017: Aurora Health Care Heart Experts Among First in Nation to Implant New Heart Valve to Treat Aortic Stenosis 229
  • 6.36 Apr 04, 2017: HLT Announces First Patient Enrollments in a Feasibility Study of a New Transcatheter Aortic Valve Replacement System 230
  • 6.37 Mar 30, 2017: MPSC Announces 2016 Annual Results 231
  • 6.38 Mar 23, 2017: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2016 232
  • 6.39 Mar 22, 2017: Medtronic Receives FDA Approval for CoreValve Evolut Pro Transcatheter Valve with Advanced Sealing 236
  • 6.40 Mar 17, 2017: Landmark SURTAVI Clinical Trial Shows Transcatheter Aortic Valve Replacement with the Self-Expanding Platform Performs as Well as Surgery in Intermediate Risk Severe Aortic Stenosis Patients 237
  • 6.41 Mar 10, 2017: Neovasc Announces TSX Symbol Change to NVCN 238
  • 6.42 Mar 09, 2017: Boston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation 238
  • 6.43 Mar 03, 2017: Colibri Heart Valve Receives ISO 13485 and EN ISO 13485 Certification 238
  • 6.44 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 239
  • 6.45 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 242
  • 6.46 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 243
  • 6.47 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 244
  • 6.48 Jan 19, 2017: LHSC First in Ontario to Implant Canadian made Mitral Valve Device 246
  • 6.49 Jan 18, 2017: Neovasc Announces Update in Litigation with CardiAQ 246
  • 6.50 Jan 17, 2017: Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies 247
  • 6.51 Dec 30, 2016: NaviGate Cardiac Structures Reports World's First Transcatheter Tricuspid Valved Stent is Successfully Implanted 247
  • 6.52 Dec 26, 2016: MicroPort Completes Patient Enrollment of VitaFlow Pre-market Clinical Trial 248
  • 6.53 Dec 23, 2016: Neovasc Announces Update in Litigation with CardiAQ 249
  • 6.54 Dec 21, 2016: AorTech International: Unaudited Interim Results For the six months ended 30 September 2016 249
  • 6.55 Dec 21, 2016: AorTech Shares Dive As Losses And Lawsuit Against Former CEO Continue 251
  • 6.56 Dec 08, 2016: Aurora Heart and Vascular team hits milestone of 1,000th valve replacement procedure at Aurora St. Luke's 251
  • 6.57 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 252
  • 6.58 Dec 06, 2016: Neovasc Provides Update On Its Tiara Mitral Valve Clinical Program 254
  • 6.59 Dec 01, 2016: Medtronic Announces Reimbursement Approval and Launch of CoreValve Evolut R System in Japan 255
  • 6.60 Nov 28, 2016: Neovasc Receives Regulatory Approval To Initiate TIARA II CE Mark Study 256
  • 6.61 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 256
  • 6.62 Nov 18, 2016: Celyad Announces Third Quarter 2016 Business Update 259
  • 6.63 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 261
  • 6.64 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 261
  • 6.65 Nov 14, 2016: Neovasc Reports Third Quarter Results for 2016 262
  • 6.66 Nov 03, 2016: Study Deems Transcaval Valve Replacement Pioneered at Henry Ford Hospital 'Successful' 264
  • 6.67 Nov 01, 2016: Medtronic Harmony Transcatheter Pulmonary Valve Demonstrates Positive Early Clinical Outcomes At One Year 265
  • 6.68 Nov 01, 2016: Edwards Sapien Valves Demonstrate Excellent Durability In 5-Year Echo Study 266
  • 6.69 Nov 01, 2016: Neovasc Announces Update in Litigation with CardiAQ 266
  • 6.70 Nov 01, 2016: Patients with Severe Aortic Stenosis and Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve replacement 267
  • 6.71 Nov 01, 2016: Xeltis Announces Multidisciplinary Scientific Advisory Board of Global Leading Experts 268
  • 6.72 Nov 01, 2016: Early And Sustained Quality Of Life Improvements Seen For Intermediate Risk Patients Treated With Edwards Transcatheter Valves 268
  • 6.73 Oct 31, 2016: New Data on Medtronic Evolut R TAVR System Show Excellent 'Real-World' Outcomes in Global Patient Population 269
  • 6.74 Oct 31, 2016: New method for performing aortic valve replacement proves successful in high risk patients 270
  • 6.75 Oct 27, 2016: The Successful Worldwide First in Human Implantation of an Innovative Aortic Valve from Colibri Heart Valve and Venus Medtech with Disruptive "Dry Tissue" Technology Conducted 271
  • 6.76 Oct 26, 2016: Neovasc to Present Tiara Data at TCT in Washington DC 272
  • 6.77 Oct 26, 2016: Medtronic Announces FDA Approval of New Recaptureable TAVR System Available for Severe Aortic Stenosis Patients with Large Anatomies 273
  • 6.78 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 273
  • 6.79 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 275
  • 6.80 Oct 24, 2016: Boston Scientific announced key Presentations on Lotus Valve System at Transcatheter Cardiovascular Therapeutics 2016 277
  • 6.81 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 278
  • 6.82 Oct 14, 2016: AorTech International Announces Board Changes 279
  • 6.83 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 280

7 Appendix 281

  • 7.1 Methodology 281
  • 7.2 About GlobalData 284
  • 7.3 Contact Us 284
  • 7.4 Disclaimer 284

List of Tables

1.1 List of Tables

  • Table 1: Transcatheter Heart Valves - Pipeline Products by Stage of Development 18
  • Table 2: Transcatheter Heart Valves - Pipeline Products by Segment 19
  • Table 3: Transcatheter Heart Valves - Pipeline Products by Territory 20
  • Table 4: Transcatheter Heart Valves - Pipeline Products by Regulatory Path 21
  • Table 5: Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date 22
  • Table 6: Transcatheter Heart Valves - Ongoing Clinical Trials 23
  • Table 7: Transcatheter Heart Valves Companies - Pipeline Products by Stage of Development 24
  • Table 8: Transcatheter Heart Valves - Pipeline Products by Stage of Development 26
  • Table 9: 4C Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 10: TMVR Implant - Product Status 29
  • Table 11: TMVR Implant - Product Description 29
  • Table 12: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 13: Transcatheter Aortic Valve Replacement - Product Status 30
  • Table 14: Transcatheter Aortic Valve Replacement - Product Description 30
  • Table 15: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 16: pTAo-TAVR - Product Status 31
  • Table 17: pTAo-TAVR - Product Description 31
  • Table 18: Annulon Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 19: Mitral Valve Replacement Device - Product Status 32
  • Table 20: Mitral Valve Replacement Device - Product Description 32
  • Table 21: AorTech International Plc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 22: AorTech Polymer Valve - Product Status 33
  • Table 23: AorTech Polymer Valve - Product Description 33
  • Table 24: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 25: Trilogy Aortic Valve System - Product Status 34
  • Table 26: Trilogy Aortic Valve System - Product Description 34
  • Table 27: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 28: ACURATE TAVR - Product Status 36
  • Table 29: ACURATE TAVR - Product Description 36
  • Table 30: Gen 4 Lotus Valve System - Product Status 36
  • Table 31: Gen 4 Lotus Valve System - Product Description 36
  • Table 32: Lotus Edge Sheath 15F - Product Status 37
  • Table 33: Lotus Edge Sheath 15F - Product Description 37
  • Table 34: Lotus Edge Valve System - 21 mm - Product Status 37
  • Table 35: Lotus Edge Valve System - 21 mm - Product Description 38
  • Table 36: Lotus Edge Valve System - 23 mm - Product Status 38
  • Table 37: Lotus Edge Valve System - 23 mm - Product Description 38
  • Table 38: Lotus Edge Valve System - 25 mm - Product Status 39
  • Table 39: Lotus Edge Valve System - 25 mm - Product Description 39
  • Table 40: Lotus Edge Valve System - 27 mm - Product Status 39
  • Table 41: Lotus Edge Valve System - 27 mm - Product Description 40
  • Table 42: Lotus Edge Valve System - 29 mm - Product Status 40
  • Table 43: Lotus Edge Valve System - 29 mm - Product Description 40
  • Table 44: Lotus Valve System - 21 mm - Product Status 41
  • Table 45: Lotus Valve System - 21 mm - Product Description 41
  • Table 46: Lotus Valve System - 23 mm - Product Status 41
  • Table 47: Lotus Valve System - 23 mm - Product Description 42
  • Table 48: Lotus Valve System - 25 mm - Product Status 42
  • Table 49: Lotus Valve System - 25 mm - Product Description 43
  • Table 50: Lotus Valve System - 27 mm - Product Status 43
  • Table 51: Lotus Valve System - 27 mm - Product Description 43
  • Table 52: Lotus Valve System - 29 mm - Product Status 44
  • Table 53: Lotus Valve System - 29 mm - Product Description 44
  • Table 54: Transaortic Sheath - Product Status 44
  • Table 55: Transaortic Sheath - Product Description 45
  • Table 56: Boston Scientific Corp - Ongoing Clinical Trials Overview 46
  • Table 57: Lotus Valve System - 23 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 49
  • Table 58: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers 49
  • Table 59: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 49
  • Table 60: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 50
  • Table 61: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 50
  • Table 62: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 50
  • Table 63: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX 51
  • Table 64: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 51
  • Table 65: Lotus Valve System - 27 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 52
  • Table 66: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 52
  • Table 67: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 52
  • Table 68: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 53
  • Table 69: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 53
  • Table 70: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX 53
  • Table 71: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 54
  • Table 72: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 54
  • Table 73: Lotus Valve System - 25 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 55
  • Table 74: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 55
  • Table 75: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 55
  • Table 76: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 56
  • Table 77: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 56
  • Table 78: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 56
  • Table 79: Lotus Valve System - 21 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 57
  • Table 80: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 57
  • Table 81: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 57
  • Table 82: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 58
  • Table 83: Lotus Valve System - 29 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 59
  • Table 84: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 59
  • Table 85: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 59
  • Table 86: Lotus Valve System - 29 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 60
  • Table 87: Lotus Edge Valve System - 23 mm - Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation 61
  • Table 88: Lotus Edge Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 61
  • Table 89: Lotus Edge Valve System - 23 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety 61
  • Table 90: Lotus Edge Valve System - 29 mm - Reprise Edge 29 Mm Eu Study: Repositionable Percutaneous Replacement of Native Stenotic Aortic Valve Through Implantation of Lotus Edge 29 Mm Valve - Evaluation of Safety and Performance 62
  • Table 91: Lotus Edge Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 63
  • Table 92: Lotus Edge Valve System - 25 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety 63
  • Table 93: Lotus Edge Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 64
  • Table 94: Lotus Edge Valve System - 27 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety 64
  • Table 95: Celyad SA Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 96: Mitral Valve Neo-chordae - Product Status 65
  • Table 97: Mitral Valve Neo-chordae - Product Description 65
  • Table 98: Cephea Valve Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 99: Mitral Valve Replacement Device - Product Status 66
  • Table 100: Mitral Valve Replacement Device - Product Description 66
  • Table 101: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 102: Two Piece Replacement Heart Valve - Product Status 67
  • Table 103: Two Piece Replacement Heart Valve - Product Description 67
  • Table 104: Clemson University Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 105: Transcatheter Bioprosthetic Heart Valve - Product Status 68
  • Table 106: Transcatheter Bioprosthetic Heart Valve - Product Description 68
  • Table 107: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 108: Colibri Aortic Heart Valve - 24mm - Product Status 69
  • Table 109: Colibri Aortic Heart Valve - 24mm - Product Description 69
  • Table 110: Colibri Aortic Heart Valve - 21mm - Product Status 70
  • Table 111: Colibri Aortic Heart Valve - 21mm - Product Description 70
  • Table 112: Colibri Aortic Heart Valve - 27mm - Product Status 70
  • Table 113: Colibri Aortic Heart Valve - 27mm - Product Description 71
  • Table 114: Colibri TAVI System - Product Status 71
  • Table 115: Colibri TAVI System - Product Description 71
  • Table 116: Delta Aortic Heart Valve - Product Status 72
  • Table 117: Delta Aortic Heart Valve - Product Description 72
  • Table 118: Venibri Transcatheter Heart Valve System - Product Status 72
  • Table 119: Venibri Transcatheter Heart Valve System - Product Description 73
  • Table 120: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 121: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Status 74
  • Table 122: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Description 74
  • Table 123: Sutureless Trans-Catheter Mitral Valve Replacement (TMVR) - Product Status 75

List of Figures

1.2 List of Figures

  • Figure 1: Transcatheter Heart Valves - Pipeline Products by Stage of Development 18
  • Figure 2: Transcatheter Heart Valves - Pipeline Products by Segment 19
  • Figure 3: Transcatheter Heart Valves - Pipeline Products by Territory 20
  • Figure 4: Transcatheter Heart Valves - Pipeline Products by Regulatory Path 21
  • Figure 5: Transcatheter Heart Valves - Pipeline Products by Estimated Approval Date 22
  • Figure 6: Transcatheter Heart Valves - Ongoing Clinical Trials 23
Back to Top